Stockholders Equity and StockBased Compensation (Tables)
|
3 Months Ended |
Mar. 31, 2021 |
|---|
| Stockholders Equity and StockBased Compensation |
|
| Schedule of Warrants Outstanding |
|
|
| March 31,
|
|
| December 31,
|
|
| Outstanding Warrants
|
| 2021
|
|
| 2020
|
|
|
|
|
|
|
|
|
|
| Issued to Investors on October 25, 2013, entitling the holders to purchase 20,833 common shares in the Company at an exercise price of $138.00 per common share up to and including April 24, 2021. In 2016, 4,954 of these warrants were exchanged for common stock, and all remaining warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in exchange for a reduced exercise price of $75.00 per share (warrants expired subsequent to March 31, 2021).
|
|
| 13,665
|
|
|
| 13,665
|
|
| Issued to Investors on November 17, 2014, entitling the holders to purchase 45,577 common shares in the Company at an exercise price of $138.60 per common share up to and including May 16, 2022. On June 30, 2016, the warrant holders agreed to new warrant terms, which excluded any potential net cash settlement provisions in order to classify them as equity in exchange for a reduced exercise price of $75.00 per share.
|
|
| 45,577
|
|
|
| 45,577
|
|
| Issued to an investment bank and subsequently transferred to a principal of the investment bank regarding the Series B Preferred Stock investment on January 30, 2018, entitling the holder to purchase 11,119 common shares in the Company at an exercise price of $18.00 per share, up to and including January 30, 2021 (warrants expired).
|
|
| —
|
|
|
| 11,119
|
|
| Total
|
|
| 59,242
|
|
|
| 70,361
|
|
|
| Schedule of Share-based Compensation, Stock Options, Activity |
|
|
| Three months ended March 31,
|
|
|
|
| 2021
|
|
| 2020
|
|
| Research and development expenses
|
| $
| —
|
|
| $
| —
|
|
| General and administrative expenses
|
|
| 60,000
|
|
|
| 6,000
|
|
| Total stock-based compensation expense
|
| $
| 60,000
|
|
| $
| 6,000
|
|
|
| Schedule of Stock option transactions of the employees |
|
|
| Options Outstanding
|
|
| Weighted Average Exercise Price
|
|
| Weighted Average Grant Date Fair Value
|
|
| Beginning of the period – January 1, 2021
|
|
| 515,847
|
|
| $
| 20.23
|
|
| $
| 14.51
|
|
| Granted
|
|
| —
|
|
|
| —
|
|
|
| —
|
|
| Exercised
|
|
| —
|
|
|
| —
|
|
|
| —
|
|
| Forfeited
|
|
| —
|
|
|
| —
|
|
|
| —
|
|
| Expired
|
|
| (711
| )
|
|
| 331.80
|
|
|
| 293.39
|
|
| End of the period - March 31, 2021
|
|
| 515,136
|
|
| $
| 19.80
|
|
| $
| 14.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options exercisable
|
|
| 465,410
|
|
| $
| 20.88
|
|
| $
| 14.84
|
|
|
| Schedule of Non-Vested Options, Activity |
|
|
| Shares
|
|
| Weighted Average Exercise Price
|
|
| Weighted Average Fair Value Grant Date
|
|
|
|
|
|
|
|
|
|
|
|
|
| Non-vested – December 31, 2019
|
|
| 84,873
|
|
|
| 10.73
|
|
|
| 5.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted
|
|
| 7,634
|
|
|
| 4.45
|
|
|
| 3.28
|
|
| Vested
|
|
| (41,552
| )
|
|
| 10.80
|
|
|
| 8.29
|
|
| Forfeited
|
|
| (1,229
| )
|
|
| 10.80
|
|
|
| 8.33
|
|
| Non-vested – December 31, 2020
|
|
| 49,726
|
|
|
| 9.71
|
|
|
| 7.44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Granted
|
|
| —
|
|
|
| —
|
|
|
| —
|
|
| Vested
|
|
| —
|
|
|
| —
|
|
|
| —
|
|
| Forfeited
|
|
| —
|
|
|
| —
|
|
|
| —
|
|
| Non-vested – March 31, 2021
|
|
| 49,726
|
|
|
| 9.71
|
|
|
| 7.44
|
|
|
| Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award |
|
|
| Stock Options Outstanding
|
|
| Stock Options Vested
|
|
|
|
| Weighted
|
|
| |
|
| |
|
| Weighted
|
|
| |
|
| |
|
|
|
| Average
|
|
| |
|
| |
|
| Average
|
|
| |
|
| |
|
|
|
| Remaining
|
|
| |
|
| Weighted
|
|
| Remaining
|
|
| |
|
| Weighted
|
|
|
|
| Contractual
|
|
| Number
|
|
| Average
|
|
| Contractual
|
|
| Number
|
|
| Average
|
|
|
|
| Life
|
|
| of
|
|
| Exercise
|
|
| Life
|
|
| of
|
|
| Exercise
|
|
| Exercise Prices
|
| -Years
|
|
| Awards
|
|
| Price
|
|
| -Years
|
|
| Awards
|
|
| Price
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ 3.82-$12.48
|
|
| 7.91
|
|
|
| 225,179
|
|
| $
| 8.04
|
|
|
| 7.96
|
|
|
| 176,332
|
|
| $
| 7.60
|
|
| $ 12.49-$24.00
|
|
| 6.32
|
|
|
| 199,790
|
|
| $
| 14.19
|
|
|
| 6.32
|
|
|
| 198,911
|
|
| $
| 14.20
|
|
| $ 24.01-$72.00
|
|
| 4.64
|
|
|
| 65,333
|
|
| $
| 55.07
|
|
|
| 4.64
|
|
|
| 65,333
|
|
| $
| 55.07
|
|
| $ 72.01-$240.00
|
|
| 4.07
|
|
|
| 24,526
|
|
| $
| 75.59
|
|
|
| 4.07
|
|
|
| 24,526
|
|
| $
| 75.59
|
|
| $ 240.01-$325.20
|
|
| 0.03
|
|
|
| 308
|
|
| $
| 325.20
|
|
|
| 0.03
|
|
|
| 308
|
|
| $
| 325.20
|
|
| Total
|
|
| 6.69
|
|
|
| 515,136
|
|
| $
| 19.80
|
|
|
| 6.58
|
|
|
| 465,410
|
|
| $
| 20.88
|
|
|
| Summary of RSUs activity |
|
|
| |
|
| Weighted
|
|
|
|
| |
|
| Average
|
|
|
|
| Number of
|
|
| Grant Date
|
|
|
|
| Shares
|
|
| Fair Value
|
|
| Total awards outstanding at January 1, 2021
|
|
| 243,800
|
|
| $
| 2.69
|
|
| Total shares granted
|
|
| —
|
|
| $
| —
|
|
| Total shares vested
|
|
| —
|
|
| $
| —
|
|
| Total shares forfeited
|
|
| —
|
|
| $
| —
|
|
| Total unvested shares outstanding at March 31, 2021
|
|
| 243,800
|
|
| $
| 2.69
|
|
|
| Scheduled vesting for outstanding RSUs awards |
|
|
| Year Ending December 31,
|
|
|
|
| 2021
|
|
| 2022
|
|
| 2023
|
|
| Total
|
|
| Scheduled vesting
|
|
| 81,268
|
|
|
| 81,267
|
|
|
| 81,265
|
|
|
| 243,800
|
|
|